The heterogeneity of breast cancer classified into luminal A/B, HER2-positive, and triple-negative subtypes—presents major therapeutic challenges, particularly for aggressive forms that resist conventional chemotherapy, endocrine therapy, and HER2-targeted agents [2, 3]. This evidence concerns the gene ERBB2 and breast cancer.